Patents by Inventor Vinay Bhaskar

Vinay Bhaskar has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11981716
    Abstract: The disclosure features fusion proteins that are conditionally active variants of IL-2. In one aspect, the full-length polypeptides of the invention have reduced or minimal cytokine-receptor activating activity even though they contain a functional cytokine polypeptide. Upon activation, e.g., by cleavage of a linker that joins a blocking moiety, e.g., a steric blocking polypeptide, in sequence to the active cytokine, the cytokine can bind its receptor and effect signaling.
    Type: Grant
    Filed: May 14, 2021
    Date of Patent: May 14, 2024
    Assignee: Werewolf Therapeutics, Inc.
    Inventors: William Winston, Daniel Hicklin, Vinay Bhaskar, Luke Evnin, Patrick Baeuerle, Jose Andres Salmeron Garcia, Heather Brodkin, Cynthia Seidel-Dugan
  • Publication number: 20230374093
    Abstract: The disclosure features fusion proteins that are conditionally active variants of IL-2. In one aspect, the full-length polypeptides of the invention have reduced or minimal cytokine-receptor activating activity even though they contain a functional cytokine polypeptide. Upon activation, e.g., by cleavage of a linker that joins a blocking moiety, e.g., a steric blocking polypeptide, in sequence to the active cytokine, the cytokine can bind its receptor and effect signaling.
    Type: Application
    Filed: October 9, 2022
    Publication date: November 23, 2023
    Inventors: William WINSTON, Daniel HICKLIN, Vinay BHASKAR, Luke EVNIN, Patrick BAEUERLE, Jose Andres SALMERON GARCIA, Heather BRODKIN, Cynthia SEIDEL-DUGAN
  • Publication number: 20230272028
    Abstract: Provided herein are separation moieties that are suitable for use in conjunction with a variety of therapeutic payloads. The separation moieties serve to generate conditionally active macromolecules whereby the macromolecules have reduced or minimal biological activity until the separation moieties are modified under specific conditions.
    Type: Application
    Filed: May 11, 2023
    Publication date: August 31, 2023
    Inventors: William WINSTON, Luke EVNIN, Vinay BHASKAR, Giselle KNUDSEN, Daniel J. HICKLIN, Cynthia SEIDEL-DUGAN, Jose Andres SALMERON-GARCIA, Heather R. BRODKIN
  • Patent number: 11739132
    Abstract: Provided herein are separation moieties that are suitable for use in conjunction with a variety of therapeutic payloads. The separation moieties serve to generate conditionally active macromolecules whereby the macromolecules have reduced or minimal biological activity until the separation moieties are modified under specific conditions.
    Type: Grant
    Filed: February 22, 2022
    Date of Patent: August 29, 2023
    Assignee: Werewolf Therapeutics, Inc.
    Inventors: William Winston, Luke Evnin, Vinay Bhaskar, Giselle Knudsen, Daniel J. Hicklin, Cynthia Seidel-Dugan, Jose Andres Salmeron Garcia, Heather R. Brodkin
  • Publication number: 20230203186
    Abstract: Provided in this disclosure are anti-CD38 binding domains, a composition comprising the anti-CD38 binding domains, nucleic acids encoding the anti-CD38 binding domains, and a method of using the anti-CD38 binding domains or the composition for treating multiple myeloma.
    Type: Application
    Filed: July 1, 2022
    Publication date: June 29, 2023
    Applicant: Takeda Pharmaceutical Company Limited
    Inventors: Kathleen Ann Elias, Gregory Landes, Shweta Singh, Wouter Korver, Andrew Walling Drake, Mary Haak-Frendscho, Vinay Bhaskar, Erin Willert
  • Publication number: 20230037373
    Abstract: Isolated antibodies that bind to human CD38 and cynomolgus CD38 are disclosed. Also disclosed are pharmaceutical compositions comprising the disclosed antibodies, and therapeutic and diagnostic methods for using the disclosed antibodies.
    Type: Application
    Filed: August 31, 2022
    Publication date: February 9, 2023
    Inventors: Kathleen Ann Elias, Gregory Landes, Shweta Singh, Wouter Korver, Andrew Walling Drake, Mary Haak-Frendscho, Gyorgy Pal Snell, Vinay Bhaskar
  • Patent number: 11535658
    Abstract: The disclosure features fusion proteins that are conditionally active variants of IL-2. In one aspect, the full-length polypeptides of the invention have reduced or minimal cytokine-receptor activating activity even though they contain a functional cytokine polypeptide. Upon activation, e.g., by cleavage of a linker that joins a blocking moiety, e.g., a steric blocking polypeptide, in sequence to the active cytokine, the cytokine can bind its receptor and effect signaling.
    Type: Grant
    Filed: November 10, 2021
    Date of Patent: December 27, 2022
    Assignee: Werewolf Therapeutics, Inc.
    Inventors: William Winston, Daniel Hicklin, Vinay Bhaskar, Luke Evnin, Patrick Baeuerle, Jose Andres Salmeron Garcia, Heather Brodkin, Cynthia Seidel-Dugan
  • Publication number: 20220324930
    Abstract: The disclosure features fusion proteins that are conditionally active variants of IL-12. In one aspect, the full-length polypeptides of the invention have reduced or minimal cytokine-receptor activating activity even though they contain a functional cytokine polypeptide. Upon activation, e.g., by cleavage of a linker that joins a blocking moiety, e.g.
    Type: Application
    Filed: April 11, 2022
    Publication date: October 13, 2022
    Inventors: William WINSTON, Daniel HICKLIN, Vinay BHASKAR, Luke EVNIN, Patrick BAEUERLE, Jose Andres SALMERON GARCIA, Heather BRODKIN, Cynthia SEIDEL-DUGAN
  • Patent number: 11453710
    Abstract: The disclosure features fusion proteins that are conditionally active variants of IL-12. In one aspect, the full-length polypeptides of the invention have reduced or minimal cytokine-receptor activating activity even though they contain a functional cytokine polypeptide. Upon activation, e.g., by cleavage of a linker that joins a blocking moiety, e.g., a steric blocking polypeptide, in sequence to the active cytokine, the cytokine can bind its receptor and effect signaling.
    Type: Grant
    Filed: May 21, 2020
    Date of Patent: September 27, 2022
    Assignee: Werewolf Therapeutics, Inc.
    Inventors: William Winston, Daniel Hicklin, Vinay Bhaskar, Luke Evnin, Patrick Baeuerle, Jose Andres Salmeron Garcia, Heather Brodkin, Cynthia Seidel-Dugan
  • Patent number: 11434304
    Abstract: Isolated antibodies that bind to human CD38 and cynomolgus CD38 are disclosed. Also disclosed are pharmaceutical compositions comprising the disclosed antibodies, and therapeutic and diagnostic methods for using the disclosed antibodies.
    Type: Grant
    Filed: October 17, 2019
    Date of Patent: September 6, 2022
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Kathleen Ann Elias, Gregory Landes, Shweta Singh, Wouter Korver, Andrew Walling Drake, Mary Haak-Frendscho, Gyorgy Pal Snell, Vinay Bhaskar
  • Patent number: 11414496
    Abstract: Provided in this disclosure are anti-CD38 binding domains, a composition comprising the anti-CD38 binding domains, nucleic acids encoding the anti-CD38 binding domains, and a method of using the anti-CD38 binding domains or the composition for treating multiple myeloma.
    Type: Grant
    Filed: January 23, 2020
    Date of Patent: August 16, 2022
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Kathleen Ann Elias, Gregory Landes, Shweta Singh, Wouter Korver, Andrew Walling Drake, Mary Haak-Frendscho, Vinay Bhaskar, Erin Willert
  • Publication number: 20220227857
    Abstract: Antibodies that modulate insulin receptor signaling are provided.
    Type: Application
    Filed: January 13, 2022
    Publication date: July 21, 2022
    Inventors: John Corbin, Mark Leslie White, Susan R. Watson, Vinay Bhaskar
  • Publication number: 20220220181
    Abstract: Provided herein are separation moieties that are suitable for use in conjunction with a variety of therapeutic payloads. The separation moieties serve to generate conditionally active macromolecules whereby the macromolecules have reduced or minimal biological activity until the separation moieties are modified under specific conditions.
    Type: Application
    Filed: February 22, 2022
    Publication date: July 14, 2022
    Inventors: William WINSTON, Luke EVNIN, Vinay BHASKAR, Giselle KNUDSEN, Daniel J. HICKLIN, Cynthia SEIDEL-DUGAN, Jose Andres SALMERON GARCIA, Heather R. BRODKIN
  • Patent number: 11352403
    Abstract: The disclosure features fusion proteins that are conditionally active variants of IL-2. In one aspect, the full-length polypeptides of the invention have reduced or minimal cytokine-receptor activating activity even though they contain a functional cytokine polypeptide. Upon activation, e.g., by cleavage of a linker that joins a blocking moiety, e.g., a steric blocking polypeptide, in sequence to the active cytokine, the cytokine can bind its receptor and effect signaling.
    Type: Grant
    Filed: May 21, 2020
    Date of Patent: June 7, 2022
    Assignee: Werewolf Therapeutics, Inc.
    Inventors: William Winston, Daniel Hicklin, Vinay Bhaskar, Luke Evnin, Patrick Baeuerle, Jose Andres Salmeron Garcia, Heather Brodkin, Cynthia Seidel-Dugan
  • Patent number: 11261247
    Abstract: Antibodies that modulate insulin receptor signaling are provided.
    Type: Grant
    Filed: March 14, 2018
    Date of Patent: March 1, 2022
    Assignee: XOMA (US) LLC
    Inventors: John Corbin, Mark Leslie White, Susan R. Watson, Vinay Bhaskar
  • Publication number: 20220056096
    Abstract: The disclosure features fusion proteins that are conditionally active variants of IL-2. In one aspect, the full-length polypeptides of the invention have reduced or minimal cytokine-receptor activating activity even though they contain a functional cytokine polypeptide. Upon activation, e.g., by cleavage of a linker that joins a blocking moiety, e.g., a steric blocking polypeptide, in sequence to the active cytokine, the cytokine can bind its receptor and effect signaling.
    Type: Application
    Filed: November 10, 2021
    Publication date: February 24, 2022
    Inventors: William WINSTON, Daniel HICKLIN, Vinay BHASKAR, Luke EVNIN, Patrick BAEUERLE, Jose Andres SALMERON GARCIA, Heather BRODKIN, Cynthia SEIDEL-DUGAN
  • Publication number: 20210403524
    Abstract: The disclosure features fusion proteins that are conditionally active variants of IL-2. In one aspect, the full-length polypeptides of the invention have reduced or minimal cytokine-receptor activating activity even though they contain a functional cytokine polypeptide. Upon activation, e.g., by cleavage of a linker that joins a blocking moiety, e.g., a steric blocking polypeptide, in sequence to the active cytokine, the cytokine can bind its receptor and effect signaling.
    Type: Application
    Filed: May 14, 2021
    Publication date: December 30, 2021
    Inventors: William WINSTON, Daniel HICKLIN, Vinay BHASKAR, Luke EVNIN, Patrick BAEUERLE, Jose Andres SALMERON GARCIA, Heather BRODKIN, Cynthia SEIDEL-DUGAN
  • Publication number: 20210115102
    Abstract: Provided herein are separation moieties that are suitable for use in conjunction with a variety of therapeutic payloads. The separation moieties serve to generate conditionally active macromolecules whereby the macromolecules have reduced or minimal biological activity until the separation moieties are modified under specific conditions.
    Type: Application
    Filed: October 28, 2020
    Publication date: April 22, 2021
    Inventors: William WINSTON, Luke EVNIN, Vinay BHASKAR, Giselle KNUDSEN, Daniel HICKLIN, Cynthia SEIDEL-DUGAN, Jose Andres SALMERON GARCIA, Heather BRODKIN
  • Publication number: 20200283490
    Abstract: The disclosure features fusion proteins that are conditionally active variants of IL-2. In one aspect, the full-length polypeptides of the invention have reduced or minimal cytokine-receptor activating activity even though they contain a functional cytokine polypeptide. Upon activation, e.g., by cleavage of a linker that joins a blocking moiety, e.g., a steric blocking polypeptide, in sequence to the active cytokine, the cytokine can bind its receptor and effect signaling.
    Type: Application
    Filed: May 21, 2020
    Publication date: September 10, 2020
    Inventors: William Winston, Daniel Hicklin, Vinay Bhaskar, Luke Evnin, Patrick Baeuerle, Jose Andres Salmeron Garcia, Heather Brodkin, Cynthia Seidel-Dugan
  • Publication number: 20200283489
    Abstract: The disclosure features fusion proteins that are conditionally active variants of IL-12. In one aspect, the full-length polypeptides of the invention have reduced or minimal cytokine-receptor activating activity even though they contain a functional cytokine polypeptide. Upon activation, e.g., by cleavage of a linker that joins a blocking moiety, e.g., a steric blocking polypeptide, in sequence to the active cytokine, the cytokine can bind its receptor and effect signaling.
    Type: Application
    Filed: May 21, 2020
    Publication date: September 10, 2020
    Inventors: William Winston, Daniel Hicklin, Vinay Bhaskar, Luke Evnin, Patrick Baeuerle, Jose Andres Salmeron Garcia, Heather Brodkin, Cynthia Seidel-Dugan